Clinical Trial Update: SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating an intravenous lentiviral gene therapy (Ivlv-X1) for X-linked severe combined immunodeficiency (SCID-X1); recruitment i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Combined Immunodeficiency
• X-linked Severe Combined Immunodeficiency

Drugs mentioned

• Ivlv-X1 (lentiviral vector-based gene therapy for SCID-X1)

Snippet

Sponsor: Shenzhen Geno-Immune Medical Institute | Conditions: SCID, X-Linked | Phase 1, Phase 2 | Status: RECRUITING